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Abstract
Characterization of long-term disease dynamics, from disease-free to end-stage, is integral to
understanding the course of neurodegenerative diseases such as Parkinson’s and Alzheimer’s;
and ultimately, how best to intervene. Natural history studies typically recruit multiple
cohorts at different stages of disease and follow them longitudinally for a relatively short
period of time. We propose a latent time joint mixed effects model to characterize long-
term disease dynamics using this short-term data. Markov chain Monte Carlo methods are
proposed for estimation, model selection, and inference. We apply the model to detailed
simulation studies and data from the Alzheimer’s Disease Neuroimaging Initiative.
Keywords: hierarchical Bayesian models, joint mixed effects models, latent time shift,
multicohort longitudinal data
1. Introduction
Disentangling the effects of normal aging from the effects of pathophysiology on neuro-
biological trajectories is crucial for predicting who will develop Alzheimer’s or other neu-
rodegenerative diseases. The determination of neurobiological trajectories is typically based
on data obtained over a relatively short time frame relative to the time span of normal ag-
ing and neurodegeneration [1]. There are four key barriers to the accurate characterization
of longitudinal trajectories of neurodegeneration and pathology in older adults: 1) late-life
trajectories can span 40 or more years; 2) there is substantial variation in the timing and
temporal dynamics of late-life trajectories; 3) study selection criteria and sampling have a
substantially different impact across age groups; and 4) there are potentially significant levels
of censoring due to death and disability in late-life that cannot be treated as independent of
pathology trajectories in most cases. Accounting for these issues is crucial to studying the
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onset, course and fluctuations of neurodegenerative diseases [2, 3], and for guiding when and
how to target interventions and preventative approaches [4]. A better understanding of how
and when to intervene necessitates the determination of dynamic networks of trajectories
of markers of cognition, function, and pathology. Long-term disease dynamics are of great
interest and importance, and have been hypothesized without rigorous methods.
Methods for longitudinal data analysis are ubiquitous. For example, generalized linear or
nonlinear mixed-effects models [5, 6] are commonly applied to model growth curves of height
or weight over time since a meaningful “time zero” (e.g. birth). However, neurodegenerative
diseases like Alzheimer’s and Parkinson’s that progress over long periods of time are typically
studied by taking longitudinal samples of multiple cohorts at different stages of disease [7, 8].
The multiple cohorts have no common meaningful time zero. Time since dementia diagnosis
might be a candidate time zero, however the transition to dementia is censored for many
individuals in the pre-dementia cohorts. Also, the dementia diagnosis is subjective and may
vary from one clinician to the next in a multicenter study. Further, dementia is not an
absorbing state and reversion to pre-dementia diagnoses occur.
We propose a latent time joint mixed effects model (LTJMM) for characterizing biomarker
trajectories in aging. The model extends joint mixed effects models [5] to include an
individual-specific latent time shift. Each individual’s latent time shift is shared across
all of their outcomes and represents the extent of their long-term disease progression. The
model is similar to others proposed for analysis of the Alzheimer’s Disease Neuroimaging
Initiative (ADNI)[7] (e.g. Jedynak et al.[9] and Donohue et al.[10]). However, the proposed
model can also accommodate covariates for fixed-effects and the Bayesian implementation
allows flexible but rigorous interrogation of the posterior distribution to make inferences
about long-term disease dynamics and the potential propagation of treatment effects from
early biomarkers to downstream cognitive and functional measures. Estimation and infer-
ence are accomplished using Hamiltonian Monte Carlo sampling as implemented in Stan [11]
and the R package rstan (Stan Development Team[12], version 2.10.1). The Stan code model
specifications and related tools for estimation and prediction are available as an additional
R package from https://bitbucket.org/mdonohue/ltjmm.
2. Methods
2.1. Latent time mixed-effects models for joint longitudinal responses
Suppose that p response variables are measured for n individuals at different follow-up
times. Follow-up may differ from subject to subject and outcome to outcome, so we denote
the measured outcome k for individual i at time j as yijk, where i = 1, . . . , n, k = 1, ..., p
and j = 1, . . . , qik. The p measured outcomes could be mixtures of binary, count, ordinal
and continuous. Assuming yijk has a distribution in the exponential family with canonical
parameter θijk, the latent time joint mixed effects model (LTJMM) is given by
hk (θijk) = ηijk = x
′
tijk
βk + γk (tijk + δi) + α0ik + α1iktijk + εijk, (1)
where hk (·) is a monotonic differentiable link function specific to the k-th outcome, ηijk
is the linear predictor for the k-th outcome from individual i at time j. The vector x′tijk
represents possibly time-varying covariates, and the vector βk is their corresponding regres-
sion coefficients. The εijk ∼ N (0, σ2k) is a measurement error term, which accounts for
outcome-specific variance.
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The parameters α0ik and α1ik are the subject and outcome specific random intercept
and slope, and δi is the subject-specific time shift shared among outcomes. “Short-term”
observation time is represented by observed covariate tijk. The parameter γk corresponds to
the outcome-specific slope with respect to “shifted” or “long-term” time tijk + δi. The time
shift δi quantifies the progression of the i-th individual relative to the population, which is
assumed to follow δi ∼ N (0, σ2δ ). And α1ik provides the information on whether individual
i is evolving faster or slower than the average individual for outcome k.
When applying the model, we typically include a fixed effect for age, as a time-varying
covariate, for each outcome. This admits two relevant rate-of-change parameters: one for
biological age and one for “disease time”. This reflects the fact that individuals can reach
the same stage of disease at different ages, and allows independent effects of healthy aging
and disease progression. The random effects accommodate additional subject to subject
variation in the level and rate of change of disease markers. The link function, hk, can be
used to accommodate any distribution from the exponential family.
A constraint must be placed on (1) to ensure model identifiability based on the observed
data without relying on informative prior distributions. In particular, to ensure identifiabil-
ity of δ, the following constraint on random intercepts is sufficient:
∑p
k=1 α0ik = 0 for all
individuals i = 1, . . . , n. A proof of identifiability is available in the supplemental material.
Model (1) can be modified to address more flexible nonlinear relationships over time by
incorporating higher-order terms or splines [13], provided these extensions maintain mono-
tonicity. Shape invariant models and self modeling regression (e.g. Kneip and Gasser[14])
similarly require positive first derivatives. Under model (1), we trivially assume that at least
one of the outcome-specific slopes γk is not equal to zero, k = 1, . . . , p. In our application,
all the outcomes are oriented to be increasing, and thus we assume all γk > 0, k = 1, . . . , p.
Finally, we explore two different distribution assumptions for random effects, namely:
1. Univariate Gaussian random effects: α0ik ∼ N (0, σ20k) and α1ik ∼ N (0, σ21k);
2. Multivariate Gaussian random effects: αi ∼ N (0,Σ),
where Σ is a covariance matrix of dimension 2p. The latter assumption allows more direct
exploration and inference regarding the correlation of response variables.
2.2. Prior specification
Since an improper prior may result in an improper posterior, we will use proper but
weakly informative priors on all the model parameters [15]. The regression parameters β
and γ are assigned independent weakly informative normalN (0, 100) priors (truncated below
by 0 for γ). Without specific information, the half-Cauchy prior is a good default choice for
scale parameters [15]. The standard deviations, i.e., σδ, σ01, · · · , σ0p, σ11, · · · , σ1p and σ, are
given weakly informative half-Cauchy priors with a small scale, i.e., half-Cauchy (0, 2.5). The
prior variance 100 for the regression parameters is chosen to be sufficiently high to be vague
enough, but sufficiently low to avoid slow mixing due to near impropriety of the posterior
[16].
To ensure efficiency and arithmetic stability, we applied the Cholesky decomposition
to the covariance matrix for the random effects, Σ, allowing us to model the standard
deviations and correlations independently. We first decomposed the covariance matrix as
Σ = ΛΩΛ, where Λ is a diagonal matrix with diagonal elements σ01, · · · , σ0p, σ11, · · · , σ1p,
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and Ω is the correlation matrix with 1’s on the diagonal and off-diagonal elements ρ. A
Choleksy decomposition gives Ω = LL′, where L is a lower triangular matrix. Furthermore,
Σ = ΛLL′Λ. During sampling, a draw is obtained from a multivariate Gaussian z ∼
N (0, I), and then the random effects are calculated as ΛLz. Here, z is regarded as a
random reparameterization and independent of ρ. As suggested in Stan [17] manual, we
imposed an LKJ prior on the correlation matrix [18].
2.3. Model comparison criteria
We use two model comparison criteria, namely, the widely applicable information cri-
terion (WAIC) [19] and the leave-one-out cross-validation information criterion (LOOIC)
[20, 21]. WAIC and LOOIC can be computed using the log-likelihood evaluated at the pos-
terior simulations of the parameter values. Both have various advantages over the deviance
information criterion (DIC). WAIC can be viewed as an improvement on DIC for Bayesian
methods [22]. We refer to Gelman et al.[23] for the detailed rationale for the preference of
WAIC to DIC. As WAIC is reported on the deviance scale [23], a difference in WAIC value
of 2 − 6 is considered as positive evidence, 6 − 10 strong evidence, and > 10 very strong
evidence [24].
Approximate LOO can be computed using raw importance sampling (IS, Gelfand et
al.[20]). Vehtari et al.[22] improved the LOO estimate using Pareto smoothed importance
sampling (PSIS) method which provides a more accurate and reliable estimate than IS.
The R package loo [25] provides tools for efficient computation of WAIC and LOOIC. The
minimum WAIC and LOOIC indicate the best fit.
3. Results
3.1. Simulation study
We conducted a simulation study to assess the model performance and assess small sample
bias. Data were generated from two candidate LTJMMs with identity link: (M1) Univariate
Gaussian random effects; (M2) Multivariate Gaussian random effects. We simulated n = 100
individuals with p = 4 outcomes and q = 4 time points each. The observation times for each
individual were sampled from a Uniform distribution tijk ∼ Uniform (0, 10). Additional
simulation parameters were set to β = (1, 0.5, 2, 0.8)′, γ = (0.2, 0.1, 0.25, 0.5)′, σδ = 4,
σ = (0.1, 0.2, 0.3, 0.25)′, σα0 = (0.5, 1, 0.8)
′, and σα1 = (1, 2, 1.5, 1)
′.
Let θˆm denote the posterior estimate of a parameter θ for the m-th simulation and let
M denote the total number of simulations. We consider the following quantities to assess
model performance: (i) total bias, Bias =
∑M
m=1
(
θˆm − θm
)
/M , (ii) total mean squared error
of prediction, MSPE =
∑M
m=1
(
θˆm − θm
)2
/M , and (iii) coverage rate of the 95% credible
intervals, C95. Results are reported and discussed in Section 3.2. Each model was simulated
M = 100 times and both models were fit to each simulated data set.
For each model fit, two parallel Markov chains were run with dispersed initial values to
diagnosis convergence. For each single chain, we ran 2 000 iterations and discarded the first
1 000 iterations as a warm-up phase, yielding a total of 2 000 samples for posterior analysis.
The remaining samples were used to calculate posterior summaries of the parameters of
interest and model comparison measurements. The potential scale reduction statistic Rˆ [26],
calculated by Stan was used to verify posterior convergence.
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3.2. Simulation study results
The estimated potential scale reduction factors were below 1.1 for all parameters, indi-
cating successful convergence. Table 1 summarizes the measures of total bias, MSPE, C95,
and the model comparison criteria for each scenario. When the data are generated from M2,
the true model is most often preferred in terms of either LOOIC (96%) or WAIC (81%).
The quartiles of the comparison criteria differences between M2 and M1 are significantly
negative, indicating strong evidence that M2 outperforms M1. When the data are generated
from M1, the models are similar, and the comparison criteria are performing as expected
and guiding us to the true model on average (LOOIC: 59% and WAIC: 65%). Models with
criteria differences smaller than two might be considered equivalent. This is expected since
M2 accommodates the association between outcomes and includes M1 as a special case. For
both scenarios, most parameters of the true model are estimated with better C95, lower bias
and MSPE, indicating good performance in terms of prediction error. Figure 1 plots the true
versus estimated individual intercepts and slopes for the first outcome, and the true versus
estimated time shifts of one simulated data set. Both plots demonstrate agreement between
the true and estimated values.
(a) (b)
Figure 1: Results of one simulated data example with 4 outcomes, 100 individuals, and at 4 time points.
(a) True value versus posterior mean of random intercepts and slopes for the first outcome. Black circle and
blue cross indicate the slope and intercept, respectively. (b) True value and posterior mean of latent time
shifts, and these are indicated in black circles. The red dashed line is an identity line (points lie close to the
line indicating a good fit).
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Table 1: Simulation study results. One hundred simulated data sets were generated under model M1 (univariate
Gaussian random effects) and model M2 (multivariate Gaussian random effects). Both models were fit to all 200
data sets.
True Model: M1 True Model: M2
Fitted Model: M1 Fitted Model: M2 Fitted Model: M1 Fitted Model: M2
Parameter Bias MSPE C95 Bias MSPE C95 Bias MSPE C95 Bias MSPE C95
β1 -0.0022 0.0086 0.96 -0.0005 0.0087 0.96 -0.0013 0.0064 0.96 -0.0016 0.0062 0.98
β2 -0.0043 0.0131 0.93 0.0003 0.0131 0.95 0.0006 0.0133 0.94 0.0020 0.0131 0.94
β3 -0.0059 0.0157 0.97 -0.0061 0.0160 0.97 -0.0041 0.0155 0.97 -0.0044 0.0147 0.97
β4 -0.0425 0.0481 0.97 -0.0409 0.0477 0.97 -0.0428 0.0550 0.95 -0.0420 0.0556 0.97
γ1 0.0274 0.0025 0.93 0.0321 0.0027 0.90 0.0305 0.0036 0.83 0.0449 0.0044 0.89
γ2 0.0194 0.0016 0.96 0.0222 0.0018 0.95 0.0246 0.0025 0.93 0.0360 0.0033 0.93
γ3 0.0265 0.0031 0.96 0.0324 0.0033 0.97 0.0388 0.0061 0.83 0.0551 0.0067 0.92
γ4 0.0398 0.0082 0.96 0.0504 0.0087 0.95 0.0529 0.0134 0.85 0.0621 0.0102 0.95
σ1 0.0006 < .0001 0.91 0.0006 < .0001 0.92 0.0006 < .0001 0.92 0.0007 < .0001 0.91
σ2 0.0020 < .0001 0.95 0.0021 < .0001 0.94 0.0009 < .0001 0.97 0.0020 < .0001 0.94
σ3 0.0023 0.0002 0.94 0.0028 0.0002 0.93 -0.0001 0.0002 0.93 0.0021 0.0002 0.94
σ4 0.0018 0.0002 0.96 0.0022 0.0002 0.96 0.0028 0.0002 0.96 0.0021 0.0002 0.96
σδ -0.2383 0.4542 0.93 -0.3312 0.4846 0.91 -0.2502 0.7656 0.84 -0.4459 0.6715 0.89
σ01 0.0142 0.0037 0.93 0.0336 0.0048 0.87 0.0162 0.0021 0.91 0.0185 0.0022 0.89
σ02 0.0061 0.0052 0.97 0.0313 0.0064 0.95 0.0298 0.0057 0.96 0.0258 0.0055 0.95
σ03 0.0033 0.0060 0.94 0.0255 0.0067 0.94 0.0262 0.0058 0.91 0.0147 0.0051 0.96
σ11 0.0078 0.0066 0.94 0.0333 0.0079 0.91 0.0067 0.0066 0.89 0.0093 0.0061 0.93
σ12 0.0114 0.0095 0.97 0.0462 0.0119 0.94 0.0122 0.0206 0.94 -0.0089 0.0183 0.95
σ13 0.0003 0.0088 0.95 0.0297 0.0101 0.92 -0.0014 0.0111 0.97 -0.0283 0.0104 0.98
σ14 0.0105 0.0053 0.96 0.0356 0.0067 0.93 0.0114 0.0064 0.97 0.0076 0.0056 0.97
% best LOOIC 59% 41% 4% 96%
% best WAIC 65% 35% 19% 81%
Quartiles (Q1,Q2,Q3) of the criteria differences between M2 and M1
LOOIC diffM2−M1 (−4.7313, 2.2414, 9.6980) (−36.2904,−24.3240,−16.4950)
WAIC diffM2−M1 (−2.0153, 2.5876, 7.4679) (−12.0306,−6.6466,−1.2454)
Note: The best performance was determined by the lowest WAIC and LOOIC among the two models for each
data and summarized as “% best” over the 100 simulations. The lower quartile, median and upper quartile
are respectively denoted by Q1, Q2 and Q3.
3.3. Application to Alzheimer’s Disease Neuroimaging Initiative
The LTJMM was fit to data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI),
which has followed volunteers diagnosed as cognitively healthy or with varying degrees of
cognitive impairment since 2005 [7]. The ADNI battery includes serial neuroimaging, cere-
brospinal fluid (CSF), and other biomarkers; and clinical and neuropsychological assess-
ments. Participants returned for repeated assessments at six months, one year, and every
year thereafter. Seven outcome measures were included in the model: CSF tau and amyloid
beta (Aβ) 1-42; PET imaging of amyloid deposition and glucose metabolism in the brain;
volumetric magnetic resonance imaging (vMRI) of the hippocampus; the 13 item Alzheimer’s
Disease Assessment Scale (ADAS13); and the Functional Activities Questionnaire (FAQ).
Fixed effect covariates for each outcome included age, carriage of the APOEε4 allele, sex,
and education. The model was fit with and without assuming a multivariate Gaussian dis-
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tribution for the random effects. Three parallel Markov chains were run for 8 000 iterations
and the first 4 000 warm-up iterations were discarded. Every fourth value of the remaining
part of each chain was stored to reduce correlation, yielding a total of 3 000 samples for
posterior analysis. The posterior mean and the 95% credible intervals were calculated using
the obtained samples for each parameter.
One goal of the analysis is to compare the long-term trends of the outcomes on a com-
parable scale and make conclusions about the temporal ordering of their emergence. With
this goal in mind, the outcome measures were transformed first to quantiles, and the quan-
tiles were then transformed by the inverse Gaussian quantile function. All the transformed
outcomes were then modeled as Gaussian with identity link. ADNI subjects were diagnosed
at their first visit with normal cognition (24%), subjective memory concern (6%), early mild
cognitive impairment (17%), late mild cognitive impairment (32%), and mild to moderate
dementia (19%). A weighted quantile transformation [27] was used so that quantiles ap-
proximate the quantiles from a sample with equal numbers of each diagnosis. Categorical
diagnosis is based, in part, on the subjective interpretation of the clinical presentation (ex-
cluding CSF and imaging data) by the physician, and hence was not included as a covariate
in LTJMMs.
We fit the LTJMMs to examine gains by incorporating correlated random effects. Fur-
thermore, we compare our proposed LTJMMs with existing models: the commonly used
linear mixed effects model (MM) with and without fixed effects for categorical baseline diag-
nosis and its interaction with time. Table 3 summarizes the model comparison results. We
found that LTJMM2 was preferred over LTJMM1 and MM without diagnosis. However, MM
with diagnosis outperformed our proposed LTJMM2 in terms of WAIC, LOOIC and DIC.
Figure 2 shows the subject-level observations (top) and predictions (bottom) according
to age. It is clear from the observations, that age explains only a small proportion of
the variance in these outcomes. The bottom panel shows that the predictions provide a
reasonable smooth of the observations and that latent time provides a reasonable ordering of
individuals according to disease severity. The posterior mean (95% credible interval) for the
latent time parameter was 14.2 (12.7 to 16.1) years (Table 2). Figure 3 shows a density plot
for the posterior mean of the subject-specific latent time by diagnosis at first ADNI visit. The
latent time estimates are temporally sorting individuals in a manner that is consistent with
physician diagnosis. Latent time parameters provide a continuous alternative to diagnosis
which is objectively derived from a comprehensive model of longitudinal measures of disease.
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Figure 2: Subject-level observed and predicted severity. The top panel shows spaghetti plots of the observed
quantiles of each outcome from all subjects in the Alzheimer’s Disease Neuroimaging Initiative with respect
to their age over time. The bottom panels show modeled trajectories for these same subjects from the fitted
LTJMM with respect to the sum of age and estimated latent time, δ. The colors indicate diagnostic severity
at first observation, from cognitively normal (blue) through dementia (red).
Abbreviations: ADAS13, Alzheimer’s Disease Assessment Scale (13 Item version); FDG, fluorodeoxyglucose;
PET, positron emission tomography; CSF, cerebrospinal fluid; FAQ, Functional Activities Questionnaire;
CN, cognitively normal; SMC, subjective memory concern; EMCI, early mild cognitive impairment; LMCI,
late mild cognitive impairment; AD, probable Alzheimer’s Disease with mild to moderate dementia.
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Figure 3: Distribution of the subject-specific latent time shifts. The estimated latent time shifts are colored
by baseline diagnostic group, a variable not included in the model. This plot suggests that the time shifts are
well aligned and consistent with diagnosis. The density plot also demonstrates that there is much overlap of
the diagnostic criteria with respect latent time.
Abbreviations: CN, cognitively normal; SMC, subjective memory concern; EMCI, early mild cognitive
impairment; LMCI, late mild cognitive impairment; AD, probable Alzheimer’s Disease with mild to moderate
dementia.
(a) Correlation between random intercepts. (b) Correlation between random slopes.
Figure 4: Posterior mean correlations among random intercepts (a) and slopes (b).
Abbreviations: ADAS13, Alzheimer’s Disease Assessment Scale (13 Item version); FDG, fluorodeoxyglucose;
PET, positron emission tomography; CSF, cerebrospinal fluid; FAQ, Functional Activities Questionnaire;
ADNI, Alzheimer’s Disease Neuroimaging Initiative.
Figure 4 shows the posterior mean of correlation parameters for random intercepts
and slopes. Not surprisingly, we see strong correlations between change in cognitive tests
(ADAS13) and the function (FAQ). However we also, see strong correlations between mea-
sures of symptomatic change (cognition and function) and biomarkers (hippocampal atrophy
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and glucose metabolism [FDG PET]). The two amyloid measures, CSF Aβ and amyloid PET,
show a moderate positive correlation for random intercepts and weakly negative correlation
of change.
Figure 5 displays the population-level predicted trajectories. The depicted curves are for
female APOEe4 carriers with the ADNI mean education. Recall that age and latent time
contribute to the model independently. For the sake of these predictions, age is calibrated so
that the ADAS13 trajectory attains the ADNI mean ADAS13 at the ADNI mean age at the
first visit. The bottom panel shows the same trajectories for progressive Alzheimer’s (red
triangles) with contrasting trajectories for healthy aging (blue dots). To obtain estimates
for healthy aging, the effect of latent time is forced to be zero to isolate the effect of age.
Figure 5: Modeled population-level severity. The top panel shows the modeled average trajectories. The
depicted evolution is for female APOEe4 carriers with the ADNI mean education. Age is calibrated so that
the ADAS13 trajectory attains the ADNI mean ADAS13 at the ADNI mean age at baseline. The bottom
panel shows the same trajectories for progressive Alzheimers (red triangles) with contrasting trajectories for
healthy aging (blue dots). For the latter, the effect of latent time is forced to be zero to isolate the effect of
age.
Abbreviations: ADAS13, Alzheimer’s Disease Assessment Scale (13 Item version); FDG, fluorodeoxyglucose;
PET, positron emission tomography; CSF, cerebrospinal fluid; FAQ, Functional Activities Questionnaire;
ADNI, Alzheimer’s Disease Neuroimaging Initiative.
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Table 2: Results of posterior estimate of parameters for the proposed LTJMM fit to seven outcomes from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI).
Parameter Posterior 95% Parameter Posterior 95%
Mean Credible Interval Mean Credible Interval
Hippocampal volume CSF Amyloid Beta 1-42
Intercept -4.102 (−4.516,−3.688) Intercept -1.454 (−2.061,−0.872)
Age 0.056 (0.052, 0.06) Age 0.016 (0.011, 0.022)
APOEε4 0.317 (0.258, 0.394) APOEε4 0.802 (0.704, 0.888)
Sex -0.288 (−0.364,−0.215) Sex -0.028 (−0.116, 0.049)
Education -0.003 (−0.015, 0.008) Education -0.012 (−0.03, 0.005)
Latent time 0.035 (0.03, 0.04) Latent time 0.035 (0.03, 0.039)
σ1 0.137 (0.134, 0.141) σ5 0.021 (0.019, 0.022)
Alzheimer’s Disease Assessment Scale Functional Activities Questionnaire
Intercept -1.089 (−1.57,−0.646) Intercept -3.012 (−3.934,−2.012)
Age 0.025 (0.02, 0.03) Age 0.035 (0.025, 0.045)
APOEε4 0.434 (0.355, 0.514) APOEε4 0.861 (0.678, 1.021)
Sex -0.246 (−0.314,−0.168) Sex -0.335 (−0.471,−0.196)
Education -0.051 (−0.064,−0.038) Education -0.061 (−0.089,−0.037)
Latent time 0.045 (0.039, 0.05) Latent time 0.096 (0.085, 0.107)
σ2 0.327 (0.32, 0.333) σ6 0.842 (0.826, 0.858)
FDG PET CSF Tau
Intercept -1.820 (−2.348,−1.3) Intercept -0.766 (−1.265,−0.202)
Age 0.028 (0.023, 0.034) Age 0.012 (0.007, 0.017)
APOEε4 0.453 (0.363, 0.54) APOEε4 0.621 (0.505, 0.72)
Sex -0.181 (−0.259,−0.103) Sex 0.073 (−0.036, 0.19)
Education -0.026 (−0.041,−0.01) Education -0.029 (−0.048,−0.007)
Latent time 0.042 (0.037, 0.048) Latent time 0.032 (0.028, 0.036)
σ3 0.294 (0.283, 0.304) σ7 0.016 (0.014, 0.017)
Amyloid PET Standard deviation of latent time
Intercept -0.685 (−1.328,−0.013) σδ 14.262 (12.684, 16.105)
Age 0.004 (−0.002, 0.011)
APOEε4 0.785 (0.669, 0.912)
Sex 0.159 (0.067, 0.247)
Education -0.007 (−0.029, 0.014)
Latent time 0.035 (0.03, 0.04)
σ4 0.289 (0.273, 0.307)
Table 3: Results of model selection for models fit to seven outcomes from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI).
Model WAIC LOOIC DIC
LTJMM1 10246.31 14156.73 11070.65
LTJMM2 9684.75 13482.41 10528.48
MM 10023.88 13938.55 11010.95
JMM 9308.89 12385.48 10170.97
MM (diagnosis) 9792.05 13778.70 10761.32
JMM (diagnosis) 9420.06 13082.31 10286.82
Note: Model comparison results for LTJMMs with univariate Gaussian random effects (LTJMM1) and with
multivariate Gaussian random effects (LTJMM2); conventional linear mixed-effects model (MM); joint mixed
effects model (JMM) with multivariate Gaussian random effects; and MM (diagnosis) and JMM (diagnosis)
with categorical baseline diagnosis and its interaction with time as additional covariates.
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4. Discussion
We explored sampling the random effects from both univariate and multivariate Gaussian
distributions, and found the multivariate is always preferred when it is the true model, and
performs similarly well when the univariate is the true model. The model with multivari-
ate random effects has the advantage of providing additional parameters for the correlation
among outcomes (random intercepts) and among change in outcomes (random slopes). How-
ever, fitting the model with univariate random effects was often computationally faster, so it
may have advantages in practice. We plan to explore extension of the model which include
monotone smooth functions of latent time, and other random effects options. Furthermore,
the variability of latent time shifts was assumed to be homogeneous (same for all individuals)
in this work. We are currently working on an extension of the model to allow heterogeneous
variances by explicitly modeling subject-specific latent time variance in terms of observed
covariates.
Interestingly, the model selection criteria preferred LTJMM over MM when the MM did
not include fixed effects for categorical baseline diagnosis. However, when the MM had the
advantage of the additional covariates for baseline diagnosis, the MM was preferred over
LTJMM. This analysis suggests LTJMM is a good alternative to MM when baseline diagno-
sis is not known or when novel insights about long-term progression across all the diagnostic
categories are desired. These long-term insights are unattainable with MM. LTJMM also
provides subject-specific latent disease-time estimates that could serve as a continuous ob-
jective alternative to categorical diagnosis.
The LTJMM provides a parsimonious extension of the existing family of joint generalized
linear mixed effects models with a subject-specific latent time parameter that accommodates
the temporal heterogeneity common to multicohort longitudinal data in late-life neurode-
generative diseases. The model provides key insights and inference regarding the evolution
of disease markers over a period of time that is longer than the period of observation. The
framework allows consideration of the independent effects of healthy aging and disease pro-
gression.
These novel features can be leveraged to improve subject-level prediction and better
understand long-term disease dynamics. In particular we plan to leverage the model to help
improve clinical trial design. For example, given an estimate of the short-term effect of a
treatment on a biomarker, the model can be interrogated to estimate the downstream effects
on cognition and function. The model can also be used to help identify populations expected
to experience the maximum benefit from a given intervention. The LTJMM provides a
flexible framework to begin to explore these and many other applications.
5. Supplementary material
The Stan code model specifications and related code and functions for simulation, estima-
tion and prediction are available as an R package from https://bitbucket.com/mdonohue/
ltjmm. Interactive convergence plots of the model fit to Alzheimer’s data is available from
https://shiny.atrihub.org/public/adni_ltjmm/.
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Appendix A. Proof of the Identifiability
Suppose that p response variables are measured for n individuals at different follow-up
times. The measured outcomes for individual i at time j are denoted as yij = (yij1, · · · , yijp)′.
The latent time joint mixed effects model is given by
yijk = x
′
ijk (tijk)βk + γk (tijk + δi) + α0ik + α1iktijk + εijk, (A.1)
where i = 1, . . . , n, k = 1, . . . , p and j = 1, . . . , qik.
The model (A.1) can be re-expressed as the form of linear mixed effects model
yijk = x
′
ijk (tijk)βk + γktijk + α˜0ik + α1iktijk + εijk, (A.2)
where α˜0ik = γkδi+α0ik. Identifiability, up to α˜0ik follows from the identifiability of standard
linear mixed effects models (see Wang (2013)2 for a discussion) provided (x′, t) has full
column rank, where t is the vector formed by tijk; and t is linearly independent from the
vector of 1’s.
By placing the sum-to-zero constraints on α0ik, i.e.,
∑p
k=1 α0ik = 0, it remains to show
the system below:
α˜0ik = γkδi + α0ik (A.3)
0 =
p∑
k=1
α0ik (A.4)
has a unique solution, where γk and α˜0ik are known, since they are identifiable in (A.2); δi and
α0ik are unknown. There are n× p unknown subject and outcome specific parameters α0ik,
and n subject-specific latent time parameters δi, for a total of np+ n unknown parameters.
There are np+n constraints (or equations). The system (A.3 & A.4) with the same number
of equations and unknown parameters has a unique solution. Therefore, δi and α0ik are
uniquely determined. Thus the model is identifiable.
2Wang, W. (2013). Identifiability of linear mixed effects models. Electronic Journal of Statistics, 7,
244-263.
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